Starling Oncology, Inc. 8K

Starling Oncology reported strong Q2 2026 results with positive Adjusted EBITDA, expanded value-based contracts, and raised its full-year 2026 revenue and gross profit guidance.

On August 6, 2026, Starling Oncology, Inc. (NASDAQ: STLN) announced its financial results for the quarter ended June 30, 2026, reporting 34.6% year-over-year revenue growth to $161.3 million, a narrowed net loss of $9.8 million, and a turn to positive Adjusted EBITDA, while highlighting strong specialty pharmacy performance, new delegated contracts in Nevada and Oregon, an exclusivity agreement with a major California partner adding approximately 230,000 capitated lives, the planned mid-August launch of its Starling Nexus provider portal, and issuing updated full-year 2026 guidance that raises expected revenue and gross profit and modestly increases the Adjusted EBITDA outlook, along with guidance for 2026 capitated revenue and Medical Loss Ratio and an outlook for Q3 2026 Adjusted EBITDA.

Filing Facts

CIK

1799191

Ticker

-

Form

8K

Source Type

sec

Accession

0001079973-26-001006

Alert Tier

6